John Moses, APRN
Family · Honolulu, HINPI 1447737481
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Alkermes, Inc. accounts for 81.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $12,740 and has fallen 60.3% since, to $5,058 in 2025. Among family clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 279 payments — averaging $86.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$19K
- Indivior Inc.$821
- AbbVie$686
- Teva Pharmaceuticals USA, Inc.$534
- Neurocrine Biosciences, Inc.$330
- Otsuka America Pharmaceutical, Inc.$309
- plus $2K from 18 others
What the payments were for
- Consulting fees$6753%
- Speaking & faculty fees$13,31555%
- Travel & lodging$2,80012%
- Food & beverage$7,18330%
- Education$430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 97 | $19,492 |
| Indivior Inc. | 24 | $821 |
| AbbVie | 33 | $686 |
| Teva Pharmaceuticals USA, Inc. | 10 | $534 |
| Neurocrine Biosciences, Inc. | 12 | $330 |
| Otsuka America Pharmaceutical, Inc. | 12 | $309 |
| Johnson & Johnson | 12 | $288 |
| Lundbeck LLC | 11 | $236 |
| Axsome Therapeutics, Inc. | 5 | $194 |
| Gilead | 14 | $158 |
| Novo Nordisk | 10 | $154 |
| Viiv Healthcare Company | 2 | $144 |
| Amarin Pharma, Inc. | 10 | $132 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 3 | $70 |
| Idorsia Pharmaceuticals US Inc | 2 | $43 |
| Esperion Therapeutics, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $41 |
| AstraZeneca | 2 | $40 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
| Biohaven Pharmaceuticals, Inc. | 2 | $25 |
| Pfizer | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$16,843
- LYBALVI$3,367
- ARISTADA$973
- SUBLOCADE$365
- ARISTADA INITIO$243
- UZEDY$235
- Austedo XR$137
- APRETUDE$125
- VRAYLAR$117
- Auvelity$115
- ABILIFY MAINTENA$102
How this compares
$24,015 in reported general payments places this provider in the 95th percentile of 466 family providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SublocadeBuprenorphine | 23 | $47,695 |
| VivitrolNaltrexone Microspheres | 12 | $19,630 |
| Invega SustennaPaliperidone Palmitate | 11 | $16,608 |
| JardianceEmpagliflozin | 13 | $8,129 |
| FetzimaLevomilnacipran Hcl | 11 | $5,647 |
| Buprenorphine Hcl | 88 | $3,229 |
| Celecoxib | 36 | $2,486 |
| Fentanyl | 24 | $2,351 |
| VascepaIcosapent Ethyl | 11 | $1,830 |
| Morphine Sulfate | 43 | $1,524 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 49 | $1,469 |
| Gabapentin | 69 | $1,041 |
| Morphine Sulfate ErMorphine Sulfate | 35 | $1,020 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 42 | $966 |
| Olanzapine | 29 | $856 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Indivior Inc.Sublocade | $821 | $47,69523 claims |
| Alkermes, Inc.Vivitrol | $19,492 | $19,63012 claims |
| Johnson & JohnsonInvega Sustenna | $288 | $16,60811 claims |
| AbbVieFetzima | $686 | $5,64711 claims |
| Lilly USA, LLCOlanzapine | $41 | $85629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 466 family providers in Hawaii.
Other family in Honolulu
- Joey SesonHonolulu$48K
- Kanna DokgoHonolulu$26K
- Leif MarzHonolulu$11K
- Ia Lynne AranaHonolulu$9K
- Josette DudoitHonolulu$8K
- Kailie WongHonolulu$6K
- Jane StinsonHonolulu$6K
- Melissa leHonolulu$6K
- Karen RowanHonolulu$6K
- Tate KusatsuHonolulu$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.